Abstract
In this narrative review, we aim to summarize recent advancements in nuclear molecular imaging techniques and their applications in BCa management. The main focus of this review is on the most relevant clinical investigations from the past 2–3 years that highlight the enhanced diagnostic and therapeutic value of these imaging modalities. A variety of radiolabeled probes introduced in molecular imaging is explored, detailing their roles in the accurate diagnosis and characterization of BCa, as well as their integration into radioligand therapy and theragnostic strategies.
Funding Information
  • Research Training Group 2375 “Tumor-targeted Drug Delivery” (331065168, 445703531, 321137804, 70113779, 70113780, 16GW0319K)
  • Clinical Research Unit CRU 5011 “Integrating emerging methods to advance translational kidney research (InteraKD)” (331065168, 445703531, 321137804, 70113779, 70113780, 16GW0319K)
  • Research Unit 2591 “Severity assessment in animal-based research” (331065168, 445703531, 321137804, 70113779, 70113780, 16GW0319K)
  • German Cancer Aid (331065168, 445703531, 321137804, 70113779, 70113780, 16GW0319K)
  • German Federal Ministry of Research and Education (331065168, 445703531, 321137804, 70113779, 70113780, 16GW0319K)

This publication has 141 references indexed in Scilit: